Health

Volume 3, Issue 1 (January 2011)

ISSN Print: 1949-4998   ISSN Online: 1949-5005

Google-based Impact Factor: 0.74  Citations  

Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone

HTML  Download Download as PDF (Size: 122KB)  PP. 13-19  
DOI: 10.4236/health.2011.31003    4,682 Downloads   8,965 Views  Citations

Affiliation(s)

.

ABSTRACT

Objectives: Testing a hypothesis, that platelet cytochrome c-oxidase (COX) activities in patients with paranoid schizophrenia, acute episode, may be linked to dynamics of their clinical patterns and quality of cognitive functioning under antipsychotic treatment. Methods: Psychopatho-logical (PANSS, NSA-16) and cognitive assess-ments; platelet COX enzymatic activity determination, post-hoc nonparametric statistical analysis. Results: Psychopathological and cognitive assessments were done and blood was sampled in patients before (at baseline) and after treatment with risperidone. Following regu- larities were found after the treatment of patients: Significant elevation of COX, wherein the higher was COX at baseline, the more prominent was decrease in PANSSneg and NSA rates; significant negative correlation between COX and executive time in cognitive tests. When the patient group was divided by median of COX at baseline into two subgroups (greater or equal median, and 20% was assigned to the first subgroup; significantly larger amount of patients with PANSSneg by <20% was assigned to the second group. Conclusions: Therapy with risperidone seems to be more effective for patients with higher COX activity at baseline, but this fact requires further study.

Share and Cite:

Burbaeva, G. , Boksha, I. , Turishcheva, M. , Savushkina, O. , Beniashvili, A. , Rupchev, G. and Morozova, M. (2011) Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone. Health, 3, 13-19. doi: 10.4236/health.2011.31003.

Cited by

[1] Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis
European Archives of …, 2022
[2] The use of antioxidant medicine as an adjunctive therapy in late-onset schizophrenia spectrum disorders
Neurology …, 2021
[3] Связь активности тромбоцитарной цитохром с с-оксидазы с отдельными клиническими параметрами депрессии у больных пожилого возраста
2021
[4] Decrease in 130 kDa-amyloid protein precursor protein (app) and APP protein ratio in schizophrenia platelets
2020
[5] Поиск биохимических параметров для индивидуального прогноза эффективности фармакотерапии эндогенных психозов
2018
[6] GLUTAMATE DEHYDROGENASE ACTIVITY IN PLATELETS OF PATIENTS WITH SCHIZOPHRENIA
2015
[7] АКТИВНОСТЬ ФЕРМЕНТОВ ГЛУТАТИОНОВОГО ОБМЕНА (ГЛУТАТИОНРЕДУКТАЗЫ И ГЛУТАТИОН-S-ТРАНСФЕРАЗЫ) В ТРОМБОЦИТАХ БОЛЬНЫХ С ЭНДОГЕННЫМИ ПСИХОЗАМИ
Здоровье и образование в XXI веке, 2015
[8] АКТИВНОСТЬ ГЛУТАМАТДЕГИДРОГЕНАЗЫ В ТРОМБОЦИТАХ БОЛЬНЫХ ШИЗОФРЕНИЕЙ
Екатеринбург-2015, 2015
[9] GLUTATHIONE-RELATED ENZYME ACTIVITIES (GLUTATHIONE REDUCTASE AND GLUTATHIONE-S-TRANSFERASE) OF PLATELETS IN PATIENTS WITH PSYCHOSIS
2015
[10] Активность цитохром с-оксидазы и количество подобного глутаминсинтетазе белка в тромбоцитах при синдроме мягкого когнитивного снижения
Zh Nevrol Psikhiatr Im SS Korsakova, 2012
[11] Активность цитохром c-оксидазы и количество подобного глутаминсинтетазе белка в тромбоцитах при синдроме мягкого когнитивного снижения
2012
[12] Поиск биохимических предикторов эффективности антипсихотической фармакотерапии
2012
[13] Белок, подобный глутаминсинтетазе, глутаматдегидрогеназа и цитохром с-оксидаза в тромбоцитах больных при первом психотическом приступе в связи с лечением
Zh Nevrol Psikhiatr Im SS Korsakova, 2011
[14] Белок, подобный глутаминсинтетазе, глутаматдегидрогеназа и цитохром с-оксидаза в тромбоцитах больных при первом психотическом приступе в связи с …
2011

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.